Display Settings:

Format

Send to:

Choose Destination

    BMC Struct Biol. 2008 Mar 17;8:17.

    Solution structure of the Legionella pneumophila Mip-rapamycin complex.

    Ceymann A, Horstmann M, Ehses P, Schweimer K, Paschke AK, Steinert M, Faber C.

    Department of Experimental Physics 5, University of Würzburg, Würzburg, Germany. asceyman@physik.uni-wuerzburg.de

    BACKGROUND: Legionella pneumphila is the causative agent of Legionnaires' disease. A major virulence factor of the pathogen is the homodimeric surface protein Mip. It shows peptidyl-prolyl cis/trans isomerase activty and is a receptor of FK506 and rapamycin, which both inhibit its enzymatic function. Insight into the binding process may be used for the design of novel Mip inhibitors as potential drugs against Legionnaires' disease. RESULTS: We have solved the solution structure of free Mip77-213 and the Mip77-213-rapamycin complex by NMR spectroscopy. Mip77-213 showed the typical FKBP-fold and only minor rearrangements upon binding of rapamycin. Apart from the configuration of a flexible hairpin loop, which is partly stabilized upon binding, the solution structure confirms the crystal structure. Comparisons to the structures of free FKBP12 and the FKBP12-rapamycin complex suggested an identical binding mode for both proteins. CONCLUSION: The structural similarity of the Mip-rapamycin and FKBP12-rapamycin complexes suggests that FKBP12 ligands may be promising starting points for the design of novel Mip inhibitors. The search for a novel drug against Legionnaires' disease may therefore benefit from the large variety of known FKBP12 inhibitors.

    PMID: 18366641 [PubMed - indexed for MEDLINE]

    PMCID: PMC2311308

    Supplemental Content

    Click here to read Click here to read

    Structures reported by this article

    Patient drug information

    • Tacrolimus (Prograf®)

      Tacrolimus is used along with other medications to prevent rejection (attack of a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. ...

    • Sirolimus (Rapamune®)

      Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.